# US 2016/0250277 A1 · Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250277 A1
- Document ID: US20160250277A1
- Status: Published application
- Kind: A1
- Application number: 15/032,351
- Filed: 2014-10-27
- Published: 2016-09-01
- Earliest claimed: 2013-10-28
- Assignees: Cara Therapeutics, Inc.
- Applicants: Cara Therapeutics, Inc.
- Inventors: Derek T. CHALMERS; James B. JONES
- Web page: https://patentgrep.com/patent/US20160250277A1

## CPC

- A61K 38/07: Tetrapeptides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 38/06: Tripeptides
- C07K 5/1016: {and aromatic or cycloaliphatic}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for preventing, inhibiting or treating nausea and/or vomiting in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject. The nausea and/or vomiting can be associated with use of an opioid, such as morphine or fentanyl. The peripherally-restricted kappa opioid receptor agonist can be an L-amino acid-containing peptide, a D-amino acid-containing peptide, or a synthetic peptide amide, such as for instance, D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4-carboxylic acid)]-OH (CR845).

## Claims

### Claim 1

A method for preventing, inhibiting or treating nausea and/or vomiting in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the mammalian subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist comprises a peptide.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist comprises one or more D-amino acids.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the peripherally restricted kappa opioid receptor agonist comprises a synthetic peptide amide having the formula:
or a stereoisomer, mixture of stereoisomers, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof;
wherein
Xaa1 is selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and β-(E)D-Ala, wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO2, —CH3, —CF3, —CN, and —CONH2, and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
Xaa2 is selected from the group consisting of (A)(A′)D-Phe, 3,4-dichloro-D-Phe, (A)(A′)(α-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala and D-Trp;
Xaa3 is selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (α-Me)D-Leu, D-Hle, D-Val, and D-Met;
Xaa4 is selected from the group consisting of (B)2D-Arg, (B)2D-Nar, (B)2D-Har, ζ-(B)D-Hlys, D-Dap, ε-(B)D-Lys, ε-(B)2-D-Lys, D-Amf, amidino-D-Amf, γ-(B)2D-Dbu, δ-(B)2α-(B′)D-Orn, D-2-amino-3(4-piperidyl)propionic acid, D-2-amino-3 (2-aminopyrrolidyl)propionic acid, D-α-amino-β-amidinopropionic acid, α-amino-4-piperidineacetic acid, cis-α,4-diaminocyclohexane acetic acid, trans-α,4-diaminocyclohexaneacetic acid, cis-α-amino-4-methylaminocyclo-hexane acetic acid, trans-α-amino-4-methylaminocyclohexane acetic acid, α-amino-1-amidino-4-piperidineacetic acid, cis-α-amino-4-guanidinocyclohexane acetic acid, and trans-α-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of H and C1-C4 alkyl, and (B′) is H or (α-Me);
W is selected from the group consisting of:
Null, provided that when W is null, Y is N;
—NH—(CH2)b— with b equal to zero, 1, 2, 3, 4, 5, or 6; and
—NH—(CH2)c—O— with c equal to 2, or 3, provided that Y is C;
the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is non-aromatic;
V is C1-C6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and R1 and R2 are directly bonded to the same or different ring atoms;
wherein (i) R1 is selected from the group consisting of —H, —OH, halo, —CF3, —NH2, —COOH, C1-C6 alkyl, C1-C6 alkoxy, amidino, C1-C6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, —CN, —CONH2, —COR′, —SO2R′, —CONR′R″, —NHCOR′, OR′ and SO2NR′R″; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, oxo, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH, and amidino; wherein R′ and R″ are each independently —H, C1-C8 alkyl, aryl, or heterocyclyl or R′ and R″ are combined to form a 4- to 8-membered ring, which ring is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, —C1-C6 alkoxy, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH and amidino; and R2 is selected from the group consisting of —H, amidino, singly or doubly C1-C6 alkyl-substituted amidino, —CN, —CONH2, —CONR′R″, —NHCOR′, —SO2NR′R″ and —COOH; or
(ii) R1 and R2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(iii) R1 and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(iv) R1 and R2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4-, 5-, 6,-, 7-, 8- and 9-membered heterocyclic ring moieties comprising R1 and R2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, optionally substituted phenyl, oxo, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring having a single ring heteroatom and e is zero, then R1 is not —OH, and R1 and R2 are not both —H;
and
provided further that when the Y and Z-containing ring moiety is a six membered ring having two ring heteroatoms, both Y and Z are N and W is null, then —(V)eR1R2 is attached to a ring atom other than Z; and if e is zero, then R1 and R2 are not both —H.

### Claim 5 (depends on 4)

The method of claim 4, wherein the moiety:
is selected from the group consisting of:

### Claim 6 (depends on 4)

The method of claim 4, wherein the synthetic peptide amide has the structure:
D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4-carboxylic acid)]-OH.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mammalian subject is a human.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is administered to the subject within 24 hours prior to, during, or within 24 hours after undergoing a medical procedure.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the medical procedure causes pain.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the peripherally-restricted kappa opioid receptor agonist is administered to the subject by a route of injection selected from the group consisting of subcutaneous injection, intravenous injection, intraperitoneal injection, intra-articular injection, and intramuscular injection.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is a non-narcotic analgesic.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is asimadoline (N-[(1S)-2-[(3S)-3 -hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide).

### Claim 13 (depends on 1)

The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is nalfurafine ((2E)-N-[(5α,6β)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]-3-(3-furyl)-N-methylacrylamide).

### Claim 14 (depends on 1)

The method according to claim 1, wherein the mammal is a human.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the nausea and/or vomiting in the human occurs within 48 hours after administration of at least one dose of a mu opioid analgesic.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the mu opioid analgesic is administered to treat, inhibit or prevent hard tissue pain.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the hard tissue pain is bone pain.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the hard tissue pain is due to a medical procedure.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the peripherally-restricted kappa opioid receptor agonist is administered prior to administration of a first dose of the mu opioid analgesic.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the peripherally-restricted kappa opioid receptor agonist is administered after administration of at least one dose of the mu opioid analgesic.
